No correlation between statin exposure and incident diabetes mellitus in HIV‐1‐infected patients receiving combination antiretroviral therapy

• Published in: HIV medicine 2016-09, Vol.17 (8), p.631-633
• Main Authors: Calza, L, Colangeli, V, Magistrelli, E, Manfredi, R, Bon, I, Re, MC, Viale, P
• Format: Article
• Language: English
• Subjects: Adult; Anti-Retroviral Agents - therapeutic use; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - therapeutic use; cardiovascular disease; diabetes mellitus; Diabetes Mellitus - epidemiology; Female; glucose; Hepatitis C virus; HIV infection; HIV Infections - complications; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Incidence; Lentivirus; Male; Middle Aged; Retrospective Studies; statin
• ISSN: 1464-2662; 1468-1293
• DOI: 10.1111/hiv.12374

Objectives Recent clinical studies and one meta‐analysis have shown a modest but significant increase in the incidence of diabetes mellitus associated with statin exposure, so this correlation was investigated in a cohort of HIV‐positive subjects. Methods A retrospective cohort study including adult HIV‐1‐infected patients followed at our Clinic of Infectious Diseases between 2007 and 2014 was performed. Results We assessed 3170 HIV‐positive patients with a median follow‐up of 5.2 years. The incidence of diabetes mellitus was 1.2 per 100 person‐years and it was not significantly associated with the prescription of statins [hazard ratio (HR) 1.09 per year of statin exposure; 95% confidence interval (CI) 0.7–1.49; P = 0.067], while it was associated with older age, chronic hepatitis C, antiretroviral‐naïve vs. antiretroviral experienced condition, high body mass index, and high serum concentration of triglycerides. Conclusions In our study, a higher risk of diabetes mellitus was not associated with statin treatment, but with some traditional risk factors.